This mutation leads to the constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, resulting in uncontrolled cell growth and proliferation [9], thus BRAF mutants has been designated as a crucial drug target for the treatment of melanoma. This evidence concerns the gene BRAF and melanoma.